https://www.live-feeds.com/feed/esmo-amgen-s-imdelltra-drives-massive-survival-benefit-in-watershed-moment-for-small-cell-lung-cancerContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/esmo-amgen-s-imdelltra-drives-massive-survival-benefit-in-watershed-moment-for-small-cell-lung-cancerhttps://www.live-feeds.com/feed/esmo-amgen-s-imdelltra-drives-massive-survival-benefit-in-watershed-moment-for-small-cell-lung-cancer#u160991Thu, 29 Oct 2026 05:54:07 +0000Amgen's Imdelltra, in combination with AstraZeneca's Imfinzi, reduced the risk of death by 58% in patients with extensive-stage small cell lung cancer. The combination extended median overall survival by 8.4 months to 21.1 months compared to Imfinzi alone. Nearly 80% of patients were alive at one year versus 53% with Imfinzi alone. This treatment approach may become a new standard of care for this aggressive form of lung cancer.Why it mattersSmall cell lung cancer is a highly aggressive and deadly form of lung cancer. Current treatment options have limited efficacy, making new therap